EGFR and non-small cell lung carcinoma: A phase II trial of first line erlotinib in chemotherapy-naïve elderly patients (≥70 years) with advanced NSCLC, unselected for EGFR, yielded a meaningful OS of 10.9 months (95% CI, 7.8–14.6 months).